Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-0105-2021

Drug recall · December 2, 2020

DOXOrubicin Hydrochloride Injection recall

Why: Cross Contamination with Other Products: trace amounts of octreotide found during testing

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05

Lots / codes

Batch: 6120525, exp 11/2020

Quantity
16,986 vials
Company
Fresenius Kabi USA, LLC, Lake Zurich, IL
Distribution
Nationwide USA and Puerto Rico
Initiated
November 17, 2020 · Voluntary: Firm initiated
Classified
November 24, 2020
Reported
December 2, 2020
Ended
August 25, 2022
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Doxorubicin

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.